Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arrowhead Pharmaceuticals (ARWR) Return on Equity (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Return on Equity for 15 consecutive years, with 0.44% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Equity rose 569.0% year-over-year to 0.44%, compared with a TTM value of 0.44% through Dec 2025, up 569.0%, and an annual FY2025 reading of 0.09%, up 264.0% over the prior year.
  • Return on Equity was 0.44% for Q4 2025 at Arrowhead Pharmaceuticals, up from 0.06% in the prior quarter.
  • Across five years, Return on Equity topped out at 0.44% in Q4 2025 and bottomed at 5.26% in Q4 2024.
  • Average Return on Equity over 5 years is 0.8%, with a median of 0.39% recorded in 2022.
  • The sharpest move saw Return on Equity crashed -394bps in 2024, then soared 569bps in 2025.
  • Year by year, Return on Equity stood at 0.47% in 2021, then increased by 19bps to 0.38% in 2022, then plummeted by -244bps to 1.31% in 2023, then tumbled by -300bps to 5.26% in 2024, then soared by 108bps to 0.44% in 2025.
  • Business Quant data shows Return on Equity for ARWR at 0.44% in Q4 2025, 0.06% in Q3 2025, and 0.26% in Q2 2025.